Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.

dc.contributor.authorCliff-Eribo, K.O.
dc.contributor.authorChoonara, I.
dc.contributor.authorDodoo, A.
dc.contributor.authorDarko, D.M.
dc.contributor.authorSammons, H.
dc.date.accessioned2018-09-14T07:55:00Z
dc.date.available2018-09-14T07:55:00Z
dc.date.issued2015-10
dc.description.abstractOBJECTIVE: The aim of this article is to describe adverse drug reactions (ADRs) reported for children aged 0 - 17 years in Ghana. METHODS: Paediatric reports submitted by the Ghana National Centre for Pharmacovigilance to the World Health Organisation (WHO) Global ADR database, VigiBase up to December 2012 were extracted. The data were analysed for number of reports per year, types of reporters and suspected ADRs and drugs. RESULTS: A total of 343 reports for children were received during the period. The drug classes most frequently reported were vaccines (115, 31%), antimalarials (106, 28%) and antibiotics (57, 15%). Of the top 20 individual drugs, 19 were anti-infectives. The most frequently reported ADRs were injection site infection, fever and rash. There were 23 deaths reported, and antimalarials were implicated in 12 cases. CONCLUSIONS: Vaccines, antimalarials and antibiotics are the leading medicines reported to cause ADRs in Ghanaian children. There was a high mortality rate, with many of the deaths due to causes explained in the individual case safety reports.en_US
dc.identifier.otherdoi: 10.1517/14740338.2015.1096927
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/24158
dc.language.isoenen_US
dc.publisherExpert Opinion on Drug Safeen_US
dc.subjectadverse drug reactionsen_US
dc.subjectchildrenen_US
dc.subjectdrug safetyen_US
dc.subjectpharmacovigilanceen_US
dc.subjectspontaneous reporting systemen_US
dc.titleAdverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.en_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: